FDA Approves BIZENGRI for NRG1+ Cholangiocarcinoma
Partner Therapeutics announced that the U.S. Food and Drug Administration has approved BIZENGRI for the treatment of adults with advanced, unresectable, or metastatic cholangiocarcinoma…
Read More...
Read More...
